Marker Therapeutics Inc (MRKR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Marker Therapeutics Inc (MRKR) has a cash flow conversion efficiency ratio of -0.102x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.40 Million) by net assets ($13.80 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Marker Therapeutics Inc (MRKR) balance sheet quality index to measure how much of total assets are equity-financed.
Marker Therapeutics Inc - Cash Flow Conversion Efficiency Trend (1999–2025)
This chart illustrates how Marker Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Marker Therapeutics Inc (MRKR) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
Marker Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Marker Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Castor Maritime Inc
NASDAQ:CTRM
|
0.019x |
|
Prakit Holdings Public Company Limited
BK:PRAKIT
|
-0.040x |
|
Gold Pacific Co. Ltd
KQ:038530
|
0.000x |
|
Green River Holding Co Ltd
TWO:8444
|
-0.174x |
|
88 Energy Ltd
AU:88E
|
-0.020x |
|
Ordinary Fully Paid Deferred Settlement
AU:88EDA
|
N/A |
|
Pensonic Holdings Bhd
KLSE:9997
|
-0.029x |
|
Smart Concrete Public Company Limited
BK:SMART
|
0.028x |
Annual Cash Flow Conversion Efficiency for Marker Therapeutics Inc (1999–2025)
The table below shows the annual cash flow conversion efficiency of Marker Therapeutics Inc from 1999 to 2025. For the full company profile with market capitalisation and key ratios, see Marker Therapeutics Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $16.80 Million | $-12.01 Million | -0.715x | -21.67% |
| 2024-12-31 | $18.56 Million | $-10.91 Million | -0.588x | +49.75% |
| 2023-12-31 | $14.05 Million | $-16.44 Million | -1.170x | +14.98% |
| 2022-12-31 | $19.60 Million | $-26.97 Million | -1.376x | -121.87% |
| 2021-12-31 | $43.99 Million | $-27.28 Million | -0.620x | +15.35% |
| 2020-12-31 | $27.34 Million | $-20.03 Million | -0.733x | -76.66% |
| 2019-12-31 | $44.09 Million | $-18.28 Million | -0.415x | -69.97% |
| 2018-12-31 | $59.34 Million | $-14.48 Million | -0.244x | +89.42% |
| 2017-12-31 | $3.66 Million | $-8.44 Million | -2.307x | -119.17% |
| 2016-12-31 | $6.18 Million | $-6.51 Million | -1.053x | -617.66% |
| 2015-12-31 | $-21.36 Million | $-4.34 Million | 0.203x | -90.48% |
| 2014-12-31 | $-1.02 Million | $-2.19 Million | 2.137x | +2597.17% |
| 2013-12-31 | $-8.77 Million | $-694.58K | 0.079x | -71.32% |
| 2012-12-31 | $-5.67 Million | $-1.57 Million | 0.276x | -27.04% |
| 2011-12-31 | $-3.46 Million | $-1.31 Million | 0.379x | +33.91% |
| 2010-12-31 | $-3.27 Million | $-925.04K | 0.283x | -84.14% |
| 2009-12-31 | $-629.39K | $-1.12 Million | 1.782x | +654.23% |
| 2008-12-31 | $-3.02 Million | $-714.42K | 0.236x | -67.71% |
| 2007-12-31 | $-1.67 Million | $-1.23 Million | 0.732x | +85.14% |
| 2006-12-31 | $-3.00 Million | $-1.19 Million | 0.395x | -24.67% |
| 2005-12-31 | $-2.22 Million | $-1.16 Million | 0.525x | +5.38% |
| 2004-12-31 | $-2.44 Million | $-1.21 Million | 0.498x | -87.63% |
| 2003-12-31 | $-643.75K | $-2.59 Million | 4.026x | +233.30% |
| 2002-12-31 | $465.83K | $-1.41 Million | -3.020x | -292.90% |
| 2000-12-31 | $-561.95K | $-879.74K | 1.566x | -72.84% |
| 1999-12-31 | $-141.42K | $-815.18K | 5.764x | -- |
About Marker Therapeutics Inc
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-assoc… Read more